MAPT and Alzheimer disease: The high sensitivity of P-Tau, and particularly the phosphorylated form at residue 181, has also been documented by other authors, to the point of being considered an easy biomarker capable of predicting pathologies characterized by tau and Aβ accumulation, discriminating between AD and other NDs, as well as identifying AD in the clinical continuum [94,95].